ICER Gives Allergan, Biohaven CGRP Inhibitors Slight Edge Over Lilly’s Reyvow

ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.

Drugs for migraine treatment
Acute therapies treat, but don't prevent, migraine attacks • Source: Shutterstock

The Institute for Clinical and Economic Review (ICER) released a final report on new acute treatments for migraine attacks on 25 February that reversed some of the drug cost watchdog’s findings from its draft report released in January, giving Allergan PLC’s Ubrelvy (ubrogepant) and Biohaven Pharmaceutical Holding Co. Ltd.’s rimegepant a slight edge over Eli Lilly & Co.’s Reyvow (lasmiditan).

ICER’s draft report issued on 10 January determined that none of the three oral drugs used on-demand to stop migraine...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip